Plasma‐derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia Vol. 28; no. 5; pp. 737 - 744
• Main Authors: Bravo, Maria Isabel, Pérez, Alba, Raventós, Aida, Grancha, Salvador, Jorquera, Juan Ignacio, Butta, Nora Viviana, Álvarez‐Román, Maria Teresa, Costa, Montserrat, Willis, Todd, Jiménez‐Yuste, Victor
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.09.2022
• Subjects: FVIII inhibitors; FVIIInull E16 Knockout mice; haemophilia A patients; haemophilia A treatment; Hemophilia; Immunoglobulin G; Patients; Plasma; plasma‐derived FVIII; recombinant FVIII; Von Willebrand factor; plasma-derived FVIII; haemophilia A treatment; von Willebrand factor; FVIIInull E16 Knockout mice; FVIII inhibitors; recombinant FVIII; haemophilia A patients
• ISSN: 1351-8216; 1365-2516
• DOI: 10.1111/hae.14589

Introduction Presence of von Willebrand factor (VWF) in FVIII concentrates offers protection against neutralizing inhibitors in haemophilia A (HA). Whether this protection is more evident in plasma‐derived (pd) FVIII/VWF or recombinant (r) FVIII concentrates remains controversial. Aim We investigated the protection exerted by VWF against FVIII inhibitors in an in vivo mouse model of HA exposed to pdFVIII/VWF or to various rFVIII concentrates. Methods Haemophilia A mice received the different FVIII concentrates after administration of vehicle or an inhibitory IgG purified from a commercial pool of HA plasma with inhibitors and FVIII:C recoveries were measured. Furthermore, using a novel clinically oriented ex vivo approach, Bethesda inhibitory activities (BU) of a commercial pool of HA plasma with inhibitors were assessed using normal plasma, or plasma from severe HA patients, without inhibitors, after treatment with the same concentrates. Results in vivo studies showed that pdFVIII/VWF offers markedly higher protection against inhibitors when compared with any of the FVIII products without VWF. More importantly, in the ex vivo studies, plasma from patients treated with pdFVIII/VWF showed higher protection against inhibitors (P values ranging .05‐.001) in comparison with that observed in plasma from patients who received FVIII products without VWF, regardless of the type of product evaluated. Conclusion Data indicate that FVIII+VWF complexes assembled in the circulation after rFVIII infusion are not equivalent to the naturally formed complex in pdFVIII/VWF. Therefore, rFVIII infused into HA patients with inhibitors would be less protected by VWF than the FVIII in pdFVIII/VWF concentrates.